Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
Titel:
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
Auteur:
Raimondi, A. Lonardi, S. Murgioni, S. Cardellino, G.G. Tamberi, S. Strippoli, A. Palermo, F. De Manzoni, G. Bencivenga, M. Bittoni, A. Chiodoni, C. Lorenzini, D. Todoerti, K. Manca, P. Sangaletti, S. Prisciandaro, M. Randon, G. Nichetti, F. Bergamo, F. Brich, S. Belfiore, A. Bertolotti, A. Stetco, D. Guidi, A. Torelli, T. Vingiani, A. Joshi, R.P. Khoshdeli, M. Beaubier, N. Stumpe, M.C. Nappo, F. Leone, A.G. Pircher, C.C. Leoncini, G. Sabella, G. Airo’ Farulla, L. Alessi, A. Morano, F. Martinetti, A. Niger, M. Fassan, M. Di Maio, M. Kaneva, K. Milione, M. Nimeiri, H. Sposito, C. Agnelli, L. Mazzaferro, V. Di Bartolomeo, M. Pietrantonio, F.